Welcome to our dedicated page for BRIGHT MINDS BIOSCIENCES SEC filings (Ticker: DRUG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bright Minds Biosciences files as a foreign issuer, and its SEC reports document clinical-stage biotechnology operations, capital formation and public-company governance. Form 6-K reports include interim condensed consolidated financial statements, management's discussion and analysis, executive certifications, material-event releases and exhibits incorporated by reference into Form F-3 registration statements.
The filings cover capital-structure disclosures for common shares, shelf registrations, public offerings and equity distribution arrangements, as well as clinical and regulatory updates for the company's 5-HT receptor agonist pipeline, including BMB-101. They also record operating and financial results, material agreements and shareholder voting matters tied to development-stage CNS drug programs.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 1,284,324 shares of Bright Minds Biosciences Inc. representing 13.1% of the class. The filing states the Asset Managers have shared voting and shared dispositive power over these shares and that the Managed Portfolios hold rights to dividends and sale proceeds. The filing identifies Janus Henderson Biotech Innovation Master Fund Ltd. as a Managed Portfolio holding more than 5% and notes an irrevocable delegation of investment and voting discretion affecting reporting status. The Schedule is signed by Kristin Mariani on 5/15/2026.
Bright Minds Biosciences Inc. ownership update: Vivo Opportunity entities amended beneficial ownership reporting to show combined holdings of certain Vivo funds and general partners. Vivo Opportunity Fund Holdings, L.P. (via Vivo Opportunity, LLC) holds 504,645 shares of Common Stock, representing 5.2% of the class. Vivo Opportunity Cayman Fund, L.P. (via Vivo Opportunity Cayman, LLC) holds 52,527 shares, representing 0.5%. The filing cites 9,787,161 shares outstanding as of February 12, 2026. All reported shares are held of record by the named partnership entities and voting and dispositive powers are stated as sole for each reported amount.
Bright Minds Biosciences Inc. Schedule 13G/A shows Cormorant Asset Management, LP and Bihua Chen report shared beneficial ownership of 950,000 common shares, representing 9.71% of the class. The filing states 9,787,161 Common Shares outstanding as of February 12, 2026. The shares are held through Cormorant Global Healthcare Master Fund, LP and reported as shared voting and dispositive power.
Cormorant Global Healthcare Master Fund, LP, an entity associated with Cormorant Asset Management and Bihua Chen, reported an open-market sale of 109,331 common shares of Bright Minds Biosciences Inc. at $89.50 per share.
After this transaction, the reporting structure shows 950,000 common shares indirectly held. The reporting persons, including Cormorant Asset Management and Bihua Chen, disclaim beneficial ownership of the reported shares except to the extent of their pecuniary interest.
Janus Henderson Group plc filed an amended Schedule 13G/A reporting beneficial ownership of 1,155,995 shares of Bright Minds Biosciences Inc. common stock, or 14.9% of the class, as of 12/31/2025.
The shares are held across various Janus Henderson asset management subsidiaries in managed client accounts, with Janus Henderson reporting shared power to vote and dispose of all 1,155,995 shares and no sole voting or dispositive power. The filing states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Bright Minds Biosciences.
Bright Minds Biosciences Inc. received an updated ownership report from Commodore Capital. Commodore Capital LP and Commodore Capital Master LP filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 18,851 common shares, representing about 0.3% of Bright Minds’ outstanding common shares.
The filing states that Commodore Capital, as investment manager to Commodore Capital Master LP, may be deemed to beneficially own these securities, with shared voting and dispositive power over all reported shares. The ownership percentage is based on 7,635,789 common shares outstanding as of September 30, 2025.
The signatory certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Bright Minds Biosciences Inc., but instead under a passive investment intent consistent with Schedule 13G requirements.
Bright Minds Biosciences Inc. received an amended Schedule 13G showing that Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. jointly report beneficial ownership of 449,290 common shares, or 4.6% of the class. This percentage is based on 9,732,161 common shares outstanding as reported in a recent prospectus supplement. The filing states the securities are not held for the purpose of changing or influencing control of the company.
Bright Minds Biosciences reported a net loss of $7.6 million for the quarter ended December 31, 2025, compared with net income of $49,610 a year earlier, as it sharply increased research and development spending.
R&D expenses rose to $5.7 million from $1.0 million, driven by expanded clinical and preclinical work and higher share-based compensation. Despite the loss, the company held $89.0 million in cash and cash equivalents and working capital of $89.2 million, and raised $13.9 million via its at-the-market program during the quarter.
Subsequently, on January 9, 2026, Bright Minds completed a public offering of 1,945,000 common shares at US$90.00 per share for gross proceeds of about US$175.1 million, further strengthening its funding for ongoing and planned trials of lead epilepsy candidate BMB-101 and other 5-HT2 programs.
Cormorant Asset Management LP and Bihua Chen report beneficial ownership of 1,059,331 Bright Minds Biosciences common shares, representing 10.88% of the class. All voting and dispositive power over these shares is shared, with no sole authority reported.
The shares are held through Cormorant Global Healthcare Master Fund, LP and related Cormorant funds. The filers state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Bright Minds Biosciences.
Bright Minds Biosciences Inc. closed a public offering of 1,945,000 common shares at US$90.00 per share, resulting in gross proceeds of US$175,050,000. The company also granted underwriters a 30-day option to buy up to an additional 291,750 common shares at the same public offering price, less underwriting discounts and commissions.
All securities in this offering were sold by Bright Minds. The company plans to use the net proceeds to fund future clinical trials for its drug candidates in absence seizures, developmental and epileptic encephalopathies, and Prader-Willi Syndrome, to initiate phase 1 clinical trials for BMB-105, to support earlier-stage research and development programs, and for general corporate and working capital purposes.